Ninety percent of therapeutic agents reaching clinical trial fail to reach entry to market, with safety concerns being a major cause for failures in phase I and II clinical trials. Drug-induced liver ...

Interest in cell therapy has increased in recent years, with additional focus on leveraging this as a strategy to fight tumors by harnessing the immune system. Cell therapy technologies include ...

For those considering adding Organ-on-a-chip (OOC) technology into the workflow, it may be unclear where to start. Firstly, using a commercially available solution, such as CN Bio's PhysioMimix ®, ...